Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Andrea Mambrini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9736-4991; OpenAlex author ID A5081700550. Sources: OpenAlex.

Their work

Papers
35
Trials
0
Grants
0
Labs led
0
Collaborators
116
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: none · 2021: 5 papers · 2022: none · 2023: 6 papers · 2024: 2 papers · 2025: 1 paper

Papers 35

  1. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  2. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  3. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  4. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  5. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  6. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  7. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  8. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  9. Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative stud… Co-author DOI 10.5306/wjco.v14.i6.215↗
  10. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  11. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  12. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  13. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  14. Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients. Co-author DOI 10.5306/wjco.v12.i11.1064↗
  15. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  16. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  17. Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients. Co-author DOI 10.1177/1534735419878505↗
  18. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  19. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  20. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  21. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  22. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  23. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Co-author DOI 10.18632/oncotarget.11041↗
  24. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  25. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  26. Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/ng.3052↗
  27. AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0108057↗
  28. A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Co-author DOI 10.2217/pgs.13.225↗
  29. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Co-author DOI 10.1002/ijc.28078↗
  30. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  31. Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Co-author DOI 10.1016/j.ejca.2013.06.041↗
  32. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/bjs.8789↗
  33. Treatment trends in metastatic pancreatic cancer patients: Is it time to change? Co-author DOI 10.1016/j.dld.2010.09.010↗
  34. Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182164002↗
  35. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Co-author DOI 10.2217/pgs.11.109↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giammaria Fiorentini · 5 shared papers, 2011–2023 · strength 0.53
  2. Carlo Milandri · 3 shared papers, 2019–2023 · strength 0.40
  3. Stefano Guadagni · 3 shared papers, 2019–2023 · strength 0.40
  4. Caterina Fiorentini · 3 shared papers, 2019–2023 · strength 0.40
  5. Maurizio Cantore · 10 shared papers, 2011–2021 · strength 0.39
  6. Elisa Giovannetti · 5 shared papers, 2011–2024 · strength 0.30
  7. Luca Morelli · 2 shared papers, 2023–2024 · strength 0.28
  8. Michèle Milella · 5 shared papers, 2011–2021 · strength 0.22
  9. Federico Canzian · 4 shared papers, 2013–2023 · strength 0.22
  10. Gabriele Capurso · 4 shared papers, 2013–2023 · strength 0.22
  11. Daniele Campa · 4 shared papers, 2013–2023 · strength 0.22
  12. Francesca Tavano · 4 shared papers, 2013–2023 · strength 0.22
  13. Pavel Souček · 4 shared papers, 2013–2023 · strength 0.22
  14. Raffaele Pezzilli · 4 shared papers, 2013–2023 · strength 0.22
  15. Tessa Y. S. Le Large · 2 shared papers, 2014–2024 · strength 0.21
  16. Niccola Funel · 6 shared papers, 2011–2017 · strength 0.20
  17. Thilo Hackert · 3 shared papers, 2016–2023 · strength 0.19
  18. Beatrice Mohelníková-Duchoňová · 3 shared papers, 2016–2023 · strength 0.19
  19. Claudio Bassi · 4 shared papers, 2011–2021 · strength 0.18
  20. Pavel Vodička · 3 shared papers, 2013–2023 · strength 0.18
  21. Stefano Landi · 3 shared papers, 2013–2023 · strength 0.18
  22. Laura L. Meijer · 1 shared paper, 2024 · strength 0.17
  23. Annalisa Comandatore · 1 shared paper, 2024 · strength 0.17
  24. Jisce R. Puik · 1 shared paper, 2024 · strength 0.17
  25. Johanna W. Wilmink · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.